Use of ghostwriters, guest authors appears frequent for studies involving rofecoxib

An examination of medical articles about rofecoxib (a nonsteroidal anti-inflammatory drug) and court documents from litigation related to this product indicates that company employees or other unacknowledged authors were frequently involved in writing clinical trial articles and review articles, but that primary authorship was often attributed to academically affiliated investigators who may have had little to do with the study, or who did not always disclose financial support from the sponsor of the study, according to an article in the April 16 issue of JAMA.

Authorship in biomedical publication provides recognition while establishing accountability and responsibility. Guest authorship has been defined as the designation of an individual who does not meet authorship criteria, according to background information in the article. Ghostwriting has been defined as the failure to designate an individual (as an author) who has made a substantial contribution to the research or writing of a manuscript.

“Recent litigation related to rofecoxib provided a unique opportunity to examine guest authorship and ghostwriting, practices that have been suspected in biomedical publication but for which there is little documentation,” the authors write.

Joseph S. Ross, M.D., M.H.S., of Mount Sinai School of Medicine, New York, and colleagues conducted a case-study review of court documents, in combination with a review of the relevant medical literature, to describe the practice of guest authorship and ghostwriting related to rofecoxib. The researchers used court documents, created predominantly between 1996 and 2004, originally obtained during litigation related to rofecoxib against Merck & Co. Inc. In addition, publicly available articles related to rofecoxib were identified via MEDLINE. Approximately 250 documents were relevant for the review.

When publishing their own clinical trials (designed, conducted, and sponsored by Merck), documents were found describing Merck scientists often working to prepare manuscripts and subsequently recruiting external, academically affiliated investigators to collaborate on the manuscript as guest authors. “Recruited authors were frequently placed in the first and second positions of the authorship list. For the publication of scientific review papers, documents were found describing Merck marketing employees developing plans for manuscripts, contracting with medical publishing companies to ghostwrite manuscripts, and recruiting external, academically affiliated investigators to be authors,” the researchers write. Documents indicated that medical publishing companies provided near complete drafts of review manuscripts to authors for editing, in addition to managing submissions and revisions.

Documents were also found describing Merck compensating investigators with honorarium for agreeing to serve as authors on review manuscripts ghostwritten on their behalf by medical publishing companies. “Among 96 relevant published articles, we found that 92 percent (22 of 24) of clinical trial articles published a disclosure of Merck’s financial support, but only 50 percent (36 of 72) of review articles published either a disclosure of Merck sponsorship or a disclosure of whether the author had received any financial compensation from the company.”

“This case-study review of industry documents related to rofecoxib demonstrates that Merck used a systematic strategy to facilitate the publication of guest authored and ghost written medical literature,” the authors write. “We are hopeful that our findings encourage discussion of ways in which to improve the integrity of research. The medical profession and the pharmaceutical industry should agree that collaborations must be conducted with the highest standards. We suggest that academic researchers consistently provide to the journals the author contributions for all manuscripts, including original research, meta-analyses, reviews, and commentaries, and disclose relationships and support from all industry sources, regardless of the journal’s requirements.”

“Authors who ‘sign-off’ on or ‘edit’ original manuscripts or reviews written explicitly by pharmaceutical industry employees or by medical publishing companies should offer full authorship disclosure, such as, ‘drafting of the manuscript was done by representatives from XYZ, Inc.; the authors were responsible for critical revisions of the manuscript for important intellectual content.’ A coordinated oversight strategy involving academic physicians, journal editors, and industry representatives is necessary to discourage both guest authorship and ghostwriting and improve the integrity of the biomedical authorship system,” the authors conclude.

Source: JAMA and Archives Journals

Related stories:

Editors' leadership role impacts on quality of biomedical research journals
The factors allowing a journal to achieve high quality are not fully understood, but good editorial practices such as accurate and author-helpful peer review and in-house editing are thought to be important. Now, a new study provides quantitative evidence that another aspect of good editorial practice – editors' expectations that articles adhere to international standards for quality reporting – is strongly related to journal quality. The research is published July 2 in the online, open-access journal PLoS ONE.
Review of online breast cancer information encourages healthy skepticism for consumers
In an extended analysis of Web pages dedicated to disseminating breast cancer information, researchers at two University of Texas institutions in the Houston have determined that while most breast cancer data found online was accurate, one in 20 breast cancer Web pages featured inaccuracies and sites displaying complementary and alternative medicine were 15 times more likely to contain false or misleading health information.
Report debunks China energy myth
A detailed analysis of powerplants in China by MIT researchers debunks the widespread notion that outmoded energy technology or the utter absence of government regulation is to blame for that country's notorious air-pollution problems. The real issue, the study found, involves complicated interactions between new market forces, new commercial pressures and new types of governmental regulation.
University professor stresses links between US Navy sonar and whale strandings
Earlier this summer, the U.S. Supreme Court agreed to review a series of lower court rulings that restrict the Navy's use of sonar in submarine detection training exercises off the coast of Southern California. The court is due to hear arguments in the case this week.
Disparities in head and neck cancer patients
A new analysis finds considerable disparities in survival related to race and socio-economic status among patients with head and neck cancer. Published in the November 15, 2008 issue of Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that earlier diagnosis and greater access to treatment could improve outcomes for these cancers among African Americans and the poor.
Scientists Find new migratory patterns for Mediterranean and Western Atlantic bluefin tuna
New research into the life cycle of Atlantic bluefin tuna shows, for the first time, that Mediterranean and North American bluefin mix substantially as juveniles, but return to their place of birth to spawn. These new research findings have critical implications for how bluefin tuna are managed on both sides of the Atlantic.
Counterintuitive physics may help everyone drive home quicker
If you're trying to drive to a destination as quickly as possible, you might think that knowing the traffic conditions would help you choose the quickest route for yourself. Traffic reports and new GPS technologies that provide traffic data are based on this assumption – but scientists have found that knowing this information may do more harm than good.
Compared to all commercial carriers, log truckers have better safety record
A report on the log truck industry just delivered to the state legislature indicates that the number of traffic accidents involving log trucks declined 11 percent while collisions for all commercial trucks increased by 15 percent in Washington between 2004 and 2006.

News discussion:

Medicine & Health news